December 23, 2020
20 min listen
Save
Dr. Mali’s Top 5 Predictions in Ophthalmology for 2021
In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.
- Intro :14
- In this episode :21
- About Yasmin P. Mali, MD :35
- Dr. Mali’s first prediction: The human spirit and innovation will triumph over the headline-dominating COVID-19 1:16
- Dr. Yasmin Mali’s thoughts on the first predictions 2:58
- Dr. Mali’s second prediction: The competition battle lines will be drawn for ocular therapeutics in the most common eye disease markets 4:04
- Thoughts on the potential products in 2021 6:25
- Dr. Mali’s third prediction: Increased use of artificial intelligence in clinical ophthalmology 8:18
- Any advances in artificial intelligence for pediatric ophthalmology? 10:15
- Dr. Mali’s fourth prediction: Telemedicine platforms will still play a role in ophthalmology 11:24
- Thoughts on telemedicine in the pediatric ophthalmology community 13:44
- Dr. Mali’s fifth prediction: Virtual ophthalmology conference options will remain present for the majority of 2021 15:17
- Dr. Mali’s thoughts on the virtual meetings attended in 2020 17:10
- Dr. Mali’s bonus announcement 18:34
- Dr. Yasmin Mali’s final words 18:48
Yasmin P. Mali, MD, is a board-certified ophthalmologist and fellowship trained pediatric ophthalmologist. Mali is currently faculty at Lake Erie College of Osteopathic Medicine in Bradenton, Florida.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Yasmin Mali, MD, reports no relevant financial disclosures.
